title: Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension.
abstract: Fixed-dose combinations (FDCs) are one of the options for improving blood pressure (BP) goal attainment. We enrolled 141 patients and evaluated the efficacy and safety between a fixed dose of olmesartan/amlodipine (OA) and a double dose of amlodipine (DA) for treating mild to moderate hypertension after amlodipine monotherapy failure. After at least 2 weeks of monotherapy failure, the patients were randomized to receive either OA or DA for 8 weeks. We compared the systolic blood pressure (SBP)-lowering efficacy of the OA and DA using both an office BP and an ambulatory blood pressure monitoring (ABPM) device. The intent-to-treat analysis found that the early (2nd week) and final visit (8th week) SBP reductions were significantly greater in those patients receiving OA (n = 70) than DA (n = 71) (17.57 ± 15.49 vs. 10.46 ± 13.36 and 24.89 ± 14.09 vs. 17.03 ± 13.27 mmHg, p = 0.002 and 0.001, respectively). Among those using ABPM, the patients with 8-week OA had a greater SBP-lowering effect in comparison with those on DA (14.08 ± 10.74 vs. 6.32 ± 10.21, p = 0.018). Both treatment strategies were well tolerated. This study showed that an OA FDC is more effective than DA in reducing SBP for mild to moderate hypertension after the failure of amlodipine monotherapy.
authors: Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Taiwan.
authors: Tsung-Hsien
authors: TH
authors: Lin
authors: Cheng-Dao
authors: CD
authors: Tsai
authors: Ju-Pin
authors: JP
authors: Pan
authors: Charles Jia-Yin
authors: CJ
authors: Hou
authors: Chien-Hsun
authors: CH
authors: Hsia
authors: Jui-Peng
authors: JP
authors: Tsai
authors: Wen-Ter
authors: WT
authors: Lai
mesh_terms: D000328:Adult; D000368:Aged; D017311:Amlodipine / Q000008:administration & dosage* / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D004359:Drug Therapy, Combination; D004487:Edema / Q000139:chemically induced; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D013777:Tetrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D007093:Imidazoles; D013777:Tetrazoles; D017311:Amlodipine; C437965:olmesartan
references: J Hypertens. 2004 Mar;22(3):653-9
references: 15076173
references: J Clin Hypertens (Greenwich). 2009 Sep;11(9):475-82
references: 19751459
references: Hypertension. 2005 May;45(5):907-13
references: 15837826
references: JAMA. 2003 May 21;289(19):2560-72
references: 12748199
references: Hypertension. 2009 Aug;54(2):181-7
references: 19581514
references: J Hypertens. 2004 Jan;22(1):11-9
references: 15106785
references: J Formos Med Assoc. 2010 Oct;109(10):740-73
references: 20970072
references: N Engl J Med. 2008 Dec 4;359(23):2417-28
references: 19052124
references: Blood Press Monit. 2011 Apr;16(2):80-6
references: 21372694
references: Lancet. 2009 Nov 21;374(9703):1765-72
references: 19811816
references: J Hypertens. 2007 Jun;25(6):1105-87
references: 17563527
references: Hypertension. 2007 Dec;50(6):991-7
references: 17954719
references: Lancet. 2002 Nov 2;360(9343):1347-60
references: 12423980
references: N Engl J Med. 2006 Jun 1;354(22):2368-74
references: 16738273
references: J Hypertens. 2008 Aug;26(8):1505-26
references: 18622223
references: J Hypertens. 2008 Mar;26(3):600-6
references: 18300873